The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary care (PCP) and oncology (ONC) provider perspectives on primary care involvement in cancer clinical trial discussions in a safety-net health system.
 
Glenda Delgado-Ramos
Research Funding - UTSW Global Health Seed; WINN Career Development Award
 
Sukh Makhnoon
No Relationships to Disclose
 
Sandi Pruitt
Consulting or Advisory Role - Pfizer
 
Kathryn Shahan
No Relationships to Disclose
 
Jessica Lee
No Relationships to Disclose
 
Rebecca Renn
Research Funding - Stand up to Cancer
 
David Gerber
Stock and Other Ownership Interests - Gilead Sciences; Walgreens
Consulting or Advisory Role - Bayer; Catalyst Pharmaceuticals; Daichi Sankyo; Jazz Pharmaceuticals; Summit Therapeutics; Taiho Oncology
Research Funding - AstraZeneca (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4287 – US Patent Application TBD INNATE AND ADAPTIVE IMMUNE FEATURES ASSOCIATED WITH TOXICITIES IN PATIENTS RECEIVING CHECKPOINT INHIBITOR THERAPY
Other Relationship - OncoSeer Diagnostics
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb